Vaccine News and Research

Latest Vaccine News and Research

Childhood vaccination rates in Texas have dropped steeply during COVID-19 pandemic

A team of researchers from universities in California and Texas has found immunization rates for children in Texas for a wide range of diseases, including polio and measles, have dropped steeply during the COVID-19 pandemic.

2 Jun 2021

Novel antibody engineering approach

Scientists from the Johns Hopkins University School of Medicine, USA, have recently developed an Antibody Display technology by grafting the second extracellular domain of tetraspanin12 (Tspan12EC2) and the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein on the heavy chain complementarity-determining region 3 (CDR3).

2 Jun 2021

Study shows how NPIs can prevent spikes in COVID-19 cases

Research published by JAMA Network Open shows how non-pharmaceutical interventions (NPIs) like mask wearing and physical distancing can help prevent spikes in COVID-19 cases as populations continue to get vaccinated.

2 Jun 2021

Old vaccines can stimulate the immune system to provide protection against other infectious diseases

Inoculation with live attenuated vaccines (LAV) such as those used against TB, polio or measles can stimulate the immune system to provide protection against other infectious diseases, including COVID-19, says a new study.

2 Jun 2021

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

An international team of scientists has identified a human molecule — biliverdin — as a potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target. The binding of the heme metabolite to the N-terminal domain of SARS-CoV-2 is associated with the virus’s ability to dodge the immune system by suppressing antibody binding to the spike protein.

2 Jun 2021

Conversations in social media platform can provide new way to communicate about vaccine efficacy

In the early days of COVID-19 vaccine development, a new social media platform provided a place for like-minded people to discuss vaccines, share misinformation and speculate about the motivations for its development.

2 Jun 2021

Is COVID-19 vaccination in California equitable yet?

Researchers from the University of California, Davis recently conducted a short investigation to examine current vaccine equity and forecasts of vaccine coverage in California by June 15, 2020, in various scenarios.

1 Jun 2021

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

1 Jun 2021

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Researchers from Ontario, Canada, recently conducted a prospective observational study to determine the SARS-CoV-2 antibody response in chronic hemodialysis patients following one vs. two doses of the BNT162b2 COVID-19 vaccine. The results were compared to health care worker controls and convalescent serum.

1 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

NIH starts Phase 1/2 clinical trial evaluating mixed COVID-19 vaccine schedules

The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens.

1 Jun 2021

Scientists use an original approach to resolve the 3D structure of flaviviruses

In a recent study, Australian scientists used an original approach to resolve the 3D structure of flaviviruses with an unprecedented level of detail, identifying small molecules known as 'pocket factors' as new therapeutic targets.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

Researchers identify common epitopes across SARS-CoV-2 viral variants

While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.

1 Jun 2021

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

Report on the effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in Canada

The report has recently been published on the preprint server medRxiv* by Kwong et al. (May 28th, 2021) and focused on the Pfizer-BioNTech or Moderna vaccines, confirming the supposed greater efficacy in preventing infection or severe outcomes following the administration of two doses.

31 May 2021

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Researchers at the Department of Viroscience, Erasmus MC, National Institute for Public Health and the Environment, Amsterdam UMC, and the Weill Medical College of Cornell University studied humoral and cellular immune responses to the wild type SARS-CoV-2, the B.1.1.7 variant (U.K. variant) and the B.1.351 variant (South African variant) in health care workers vaccinated with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine.

31 May 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A recent study conducted at the Ohio State University, USA, and the Fudan University, China, has revealed that alpha-defensin human neutrophil peptide 1 (HNP1), a cationic antimicrobial peptide, can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from infecting cells by destabilizing the viral spike protein and disrupting spike-mediated viral envelop – host cell membrane fusion.

31 May 2021

A call to action to share 2 billion doses of COVAX in 2021

Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalizations decrease and early signs of some kind of normality resume.

31 May 2021

Vaccine News and Research

Latest Vaccine News and Research

Childhood vaccination rates in Texas have dropped steeply during COVID-19 pandemic

Novel antibody engineering approach

Study shows how NPIs can prevent spikes in COVID-19 cases

Old vaccines can stimulate the immune system to provide protection against other infectious diseases

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

Conversations in social media platform can provide new way to communicate about vaccine efficacy

Is COVID-19 vaccination in California equitable yet?

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

NIH starts Phase 1/2 clinical trial evaluating mixed COVID-19 vaccine schedules

Scientists use an original approach to resolve the 3D structure of flaviviruses

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers identify common epitopes across SARS-CoV-2 viral variants

Using Sotrovimab to treat COVID-19 early

Report on the effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in Canada

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A call to action to share 2 billion doses of COVAX in 2021

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in